UK markets closed

Acurx Pharmaceuticals, Inc. (ACXP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0000-0.3000 (-9.09%)
At close: 04:00PM EDT
3.0000 0.00 (0.00%)
After hours: 04:49PM EDT

Acurx Pharmaceuticals, Inc.

259 Liberty Avenue
Staten Island, NY 10305
United States
917-533-1469
https://www.acurxpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees3

Key executives

NameTitlePayExercisedYear born
Mr. Robert J. DeLucciaCo-Founder & Exec. Chairman464.77kN/A1946
Mr. David P. Luci CPA, CPA, Esq., J.D.Corp. Sec., Co-Founder, Pres, CEO & Director443.14kN/A1967
Mr. Robert G. Shawah CPA, CPACo-Founder & CFO200.34kN/A1967
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.

Corporate governance

Acurx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.